Your session is about to expire
← Back to Search
GM1 for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
Study Summary
This trial is testing a natural nerve protector to see if it can reduce or prevent chemotherapy-induced nerve damage in breast cancer patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I understand the benefits and risks of participating in this trial.I can speak and/or read English or Spanish.I am not planning to receive immunotherapy alongside other treatments.I am 18 years old or older.I haven't had a serious lung infection or infectious diarrhea in the last 14 days.Your creatinine levels are not higher than 1.5 times the upper limit of normal.I have never been treated with GM1.You have enough infection-fighting white blood cells in your body.I am not pregnant or nursing and have a recent negative pregnancy test.Your AST or ALT levels are not more than 2.5 times the upper limit of normal.I am not planning to use cold treatments or compression therapies as part of my care.I have never been diagnosed with a neurological or psychiatric disorder.I experience little to no numbness, tingling, or pain in my hands and feet.I haven't had a stroke in the last 6 months.I can take care of myself and am up and about more than half of my waking hours.Your total bilirubin level should be less than or equal to 1.5 times the upper limit of normal.I have not been diagnosed with fibromyalgia.I have a confirmed diagnosis of metastatic breast cancer.N/AI am not planning to take duloxetine.You have enough platelets in your blood (at least 100,000 per cubic millimeter).I am scheduled to receive paclitaxel for my metastatic cancer.
- Group 1: Arm I (paclitaxel, GM1)
- Group 2: Arm II (paclitaxel, placebo)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is recruitment for this trial ongoing?
"This trial is currently enrolling participants, as indicated by the clinicaltrials.gov website. It was initially posted on May 31st of 2023 and recently updated August 2nd of 2023."
How many participants is this research study accepting?
"Affirmative. Clinicaltrials.gov hosts evidence that this medical investigation is actively seeking participants, with the original posting on May 31st 2023 and last edit taking place August 2nd of the same year. 98 individuals will be admitted at 5 distinct sites for this research endeavour."
To what degree has Arm I (paclitaxel, GM1) been determined to be safe for individuals?
"Arm I (paclitaxel, GM1) was rated a 2 on our team's safety scale as it is only in Phase 2. While some evidence for safety exists, there is no data yet to verify efficacy."
What beneficial consequences are expected to result from this clinical trial?
"The primary objective assessed over 12 months is to identify the Maximum Tolerated Dose (Early phase). Secondary endpoints involve longitudinally measured patient-reported outcomes of aches/pains at its least and on average as well as a percentage count of recipients receiving full planned doses of paclitaxel. To analyze this, penalized splines will be applied in non-parametric fashion for time trends while parametric models are used to assess intervention effects on changes in mean response. Generalised estimating equations with empirical variance estimators are also employed when comparing arms."
Share this study with friends
Copy Link
Messenger